Mutations in MUSK causing congenital myasthenic syndrome impair MuSK-Dok-7 interaction.
We describe a severe congenital myasthenic syndrome (CMS) caused by two missense mutations in the gene encoding the muscle specific receptor tyrosine kinase (MUSK). The identified MUSK mutations M605I and A727V are both located in the kinase domain of MuSK. Intracellular microelectrode recordings and microscopy studies of the neuromuscular junction conducted in an anconeus muscle biopsy revealed decreased miniature endplate potential amplitudes, reduced endplate size and simplification of secondary synaptic folds, which were consistent with postsynaptic deficit. The study also showed a striking reduction of the endplate potential quantal content, consistent with additional presynaptic failure. Expression studies in MuSK deficient myotubes revealed that A727V, which is located within the catalytic loop of the enzyme, caused severe impairment of agrin-dependent MuSK phosphorylation, aggregation of acetylcholine receptors (AChRs) and interaction of MuSK with Dok-7, an essential intracellular binding protein of MuSK. In contrast, M605I, resulted in only moderate impairment of agrin-dependent MuSK phosphorylation, aggregation of AChRs and interaction of MuSK with Dok-7. There was no impairment of interaction of mutants with either the low-density lipoprotein receptor-related protein, Lrp4 (a co-receptor of agrin) or with the mammalian homolog of the Drosophila tumorous imaginal discs (Tid1). Our findings demonstrate that missense mutations in MUSK can result in a severe form of CMS and indicate that the inability of MuSK mutants to interact with Dok-7, but not with Lrp4 or Tid1, is a major determinant of the pathogenesis of the CMS caused by MUSK mutations.
Maselli
Ricardo A
RA
Department of Neurology, School of Veterinary Medicine, University of California Davis, Davis, CA 95618, USA. ramaselli@ucdavis.edu
Arredondo
Juan
J
Cagney
Orla
O
Ng
Jarae J
JJ
Anderson
Jennifer A
JA
Williams
Colette
C
Gerke
Bae J
BJ
Soliven
Betty
B
Wollmann
Robert L
RL
D018171:Agrin / Q000378:metabolism; D000818:Animals; D002460:Cell Line; D005260:Female; D050956:HSP40 Heat-Shock Proteins / Q000378:metabolism; D006801:Humans; D051379:Mice; D009124:Muscle Proteins / Q000378:metabolism*; D018482:Muscle, Skeletal / Q000378:metabolism / Q000473:pathology / Q000502:physiology; D020125:Mutation, Missense; D020294:Myasthenic Syndromes, Congenital / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D009469:Neuromuscular Junction / Q000378:metabolism / Q000648:ultrastructure; D017433:Protein Structure, Secondary; D020794:Receptor Protein-Tyrosine Kinases / Q000737:chemistry / Q000235:genetics* / Q000378:metabolism; D011950:Receptors, Cholinergic / Q000737:chemistry / Q000235:genetics* / Q000378:metabolism; D017978:Receptors, Growth Factor / Q000378:metabolism; D055815:Young Adult
D018171:Agrin; C120664:DNAJA3 protein, human; C511692:DOK7 protein, human; D050956:HSP40 Heat-Shock Proteins; D009124:Muscle Proteins; D011950:Receptors, Cholinergic; D017978:Receptors, Growth Factor; C080030:agrin receptor; C095714:MUSK protein, human; D020794:Receptor Protein-Tyrosine Kinases